Lotiglipron
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Pfizer · Phase 2 · Terminated · Enrollment 902
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| PF-07081532 20 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 40 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 80 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 160 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 260 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| Placebo T2DM | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 80 mg Obesity | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 140 mg Obesity | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 1) | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 2) | n/r | n/r | n/r | n/r | n/r |
| PF-07081532 260 mg Obesity | n/r | n/r | n/r | n/r | n/r |
| Rybelsus 14 mg T2DM | n/r | n/r | n/r | n/r | n/r |
| Placebo Obesity | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.